SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Biotechnology-derived food crops are currently being developed in Malaysia mainly for disease resistance and improved post harvest quality. The modern biotechnology approach is adopted because of its potential to overcome constraints faced by conventional breeding techniques. Research on the development of biotechnology-derived papaya, pineapple, chili, passion fruit, and citrus is currently under way. Biotechnology-derived papaya developed for resistance to papaya ringspot virus (PRSV) and improved postharvest qualities is at the field evaluation stage. Pineapple developed for resistance to fruit black heart disorder is also being evaluated for proof-of-concept. Other biotechnology-derived food crops are at early stages of gene cloning and transformation. Activities and products involving biotechnology-derived crops will be fully regulated in the near future under the Malaysian Biosafety Law. At present they are governed only by guidelines formulated by the Genetic Modification Advisory Committee (GMAC), Malaysia. Commercialization of biotechnology-derived crops involves steps that require GMAC approval for all field evaluations and food-safety assessments before the products are placed on the market. Public acceptance of the biotechnology product is another important factor for successful commercialization. Understanding of biotechnology is generally low among Malaysians, which may lead to low acceptance of biotechnology-derived products. Initiatives are being taken by local organizations to improve public awareness and acceptance of biotechnology. Future research on plant biotechnology will focus on the development of nutritionally enhanced biotechnology-derived food crops that can provide more benefits to consumers.
India has embarked upon a very ambitious program in biotechnology with a view to harnessing its available human and unlimited biodiversity resources. It has mainly been a government sponsored effort with very little private industry participation in investment. The Department of Biotechnology (DBT) established under the Ministry of Science and Technology in 1986 was the major instrument of action to bring together most talents, material resources, and budgetary provisions. It began sponsoring research in molecular biology, agricultural and medical sciences, plant and animal tissue culture, biofertilizers and biopesticides, environment, human genetics, microbial technology, and bioprocess engineering, etc. The establishment of a number of world class bioscience research institutes and provision of large research grants to some existing universities helped in developing specialized centres of biotechnology. Besides DBT, the Department of Science & Technology (DST), also under the Ministry of S&T, sponsors research at universities working in the basic areas of life sciences. Ministry of Education's most pioneering effort was instrumental in the creation of Biochemical Engineering Research Centre at IIT Delhi with substantial assistance from the Swiss Federal Institute of Technology, Zurich, Switzerland to make available state-of-the-art infrastructure for education, training, and research in biochemical engineering and biotechnology in 1974. This initiative catalysed biotechnology training and research at many institutions a few years later. With a brief introduction, the major thrust areas of biotechnology development in India have been reviewed in this India Paper which include education and training, agricultural biotechnology, biofertilizers and biopesticides, tissue culture for tree and woody species, medicinal and aromatic plants, biodiversity conservation and environment, vaccine development, animal, aquaculture, seri and food biotechnology, microbial technology, industrial biotechnology, biochemical engineering and associated activities such as creation of biotechnology information system and national repositories. Current status of intellectual property rights has also been discussed. Contribution to the India's advances in biotechnology by the industry, excepting a limited few, has been far below expectations. The review concludes with some cautious notes.
Pharmaceutical biotechnology is developing rapidly both in academic institutions and in the biopharmaceutical industry. For this reason, FIP Special Interest Group of Pharmaceutical Biotechnology decided to develop a questionnaire concerning pharmaceutical biotechnology education. After preliminary studies were completed, questionnaires were sent to the leading scientists in academia and research directors or senior managers of various Pharmaceutical Biotechnology Companies in order to gather their views about how to create a satisfactory program. The objectives of this study were as follows: -To review all of the graduate and undergraduate courses which are presently available worldwide on pharmaceutical biotechnology in Faculties of Pharmacy. -To review all of the text books, references and scientific sources available worldwide in the area of pharmaceutical biotechnology. When replying to the questionnaires, the respondents were asked to consider the present status of pharmaceutical biotechnology education in academia and future learning needs in collaboration with the biotechnology industry. The data from various pharmacy faculties and biotechnology industry representatives from Asia, Europe and America were evaluated and the outcome of the survey showed that educational efforts in training qualified staff in the rapidly growing field of pharmaceutical biotechnology is promising. Part of the results of this questionnaire study have already been presented at the 57th International Congress of FIP Vancouver, Canada in 1997.
Thailand is very much aware of the potential and the opportunities in biotechnology and has given the utmost effort into the development of biotechnology. In 1983, the government has set up the National Center for Genetic Engineering and Biotechnology (NCGEB). The center operates through a network of research institutes and laboratories in order to maximize and consolidate the limited resources of the country. The center also plays a key role in formulating policies and plans relating to biotechnology as well as in supporting and coordinating biotechnology research and development. A sum of U.S. $8.6 million has been allocated for an initial 5-year program for R D & E activities. The priority consideration is on utilizing various levels of biotechnology for improvement in agriculture, industrial productivity, health, and environment. To facilitate and strengthen the link between research institutions and the private sector, the high-level Science and Technology Development Board (STDB) was established in 1986, with an initial allocation of U.S. $2.9 million between 1986 to 1992 for biotechnology. At present, there are between 400 to 500 scientists and technologists with M.S. or higher degrees actively working in research and development (R & D) in biotechnology and engineering, mostly in universities and government research laboratories. It is expected that approximately 500 graduates with advanced degrees in biotechnology and related fields will be produced during the 5-year plan (1987 to 1991).
There are two basic remarks that must be made about this series of articles on the theme 'Modern biotechnology: a blessing or concern?'. Firstly, it is difficult to define what 'biotechnology' is due to the diversity of techniques employed. Secondly, it is striking how biotechnological techniques may be employed for such a wide variety of goals. In this article, the ethics of using biotechnology within veterinary science and research will be discussed. Aside from its usefulness to humankind, an animal has its own value as a living creature; a fact that we should always take into account. Ethical issues such as the health, welfare and integrity of animals are discussed here in relation to developments in biotechnology. These ethical arguments reveal that biotechnology does not always have a positive impact on animals. This does not necessarily mean that biotechnology should be rejected out of hand, but that it is essential that the purpose for which the animals are being used be adequately justified. In this regard, the veterinarian may play a unique role as the guardian of both animal and human health. The veterinary profession, in all its diversity, is a participant in the development and (future) practical application of biotechnological techniques. Changes in the broader society and within the veterinary profession may continue to play a role in the societal discourse on biotechnology and its practical application, it must actively consider the ethical aspects and consequences of these scientific developments.
Biotechnology is an industry with very strong links to basic science. Therefore, the commercialisation of biotechnology draws heavily on public funded research. All European countries have developed policies to support biotechnology. This contribution gives an overview of public funding activities in all European member states during the 90s and identifies the biotechnology areas which received funding in the different countries. About 50% of all funds were channelled to biomedical research. Plant biotechnology, industrial biotechnology, and the cell factory were other important targets of public funding. Other fields such as animal biotechnology, environmental biotechnology, and non-technical areas of biotechnology were largely ignored by public funding in most European countries. Future funding trends indicate that this pattern will be mainly preserved.